Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT03078907
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose other
- Phase
- Phase 4
- Enrolled
- 108 participants
- Sponsor
- Registry
-
NCT03078907
-
- Other papers using this trial's data
- Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, France, Germany, Ireland, Norway, Portugal, Sweden, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03078907. Randomized; quadruple masking; primary purpose other. Start 2017-11-08 (actual); primary completion 2020-02-10 (actual). Results posted on 2021-02-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
- Acronym
- TRACE
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Selexipag
- Intervention (Drug)
- Placebo
- Lead sponsor
- Actelion
Record details
- Record id
cardio:ct-nct03078907- Content hash
cbe0ed907b67dbedbb020105a548f02eb958bf45ce71aa85c28461e8b9ffe116